GLPwatch
Papers (10376)
Page 79 of 173, ranked by citation count.
- Quantitative Impact of Plasma Clearance and Down-regulation on GLP-1 Receptor Molecular Imaging.
- Cardioprotective effects of liraglutide pretreatment on isoprenaline-induced myocardial injury in rats.
- Liraglutide for treating type 1 diabetes.
- Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice.
- Acute effects of the glucagon-like peptide-1 receptor agonist, exenatide, on blood pressure and heart rate responses to intraduodenal glucose infusion in type 2 diabetes.
- Liraglutide Protects Neurite Outgrowth of Cortical Neurons Under Oxidative Stress though Activating the Wnt Pathway.
- Tolerability and safety of the new anti-obesity medications.
- Effect of baseline body mass index on glycemic control and weight change with exenatide monotherapy in Chinese drug-naïve type 2 diabetic patients.
- Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
- Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
- Long-Term Liraglutide Administration Induces Pancreas Neogenesis in Adult T2DM Mice.
- GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes.
- Effect of liraglutide on lipids in patients with type 2 diabetes: a pilot study.
- Differential effects of intra-ventral tegmental area ghrelin and glucagon-like peptide-1 on the stimulatory action of D-amphetamine and cocaine-induced ethanol intake in male Sprague Dawley rats.
- Development of an <sup>111</sup>In-Labeled Glucagon-Like Peptide-1 Receptor-Targeting Exendin-4 Derivative that Exhibits Reduced Renal Uptake.
- Follow the LEADER-Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial.
- Enhanced Peptide Stability Against Protease Digestion Induced by Intrinsic Factor Binding of a Vitamin B12 Conjugate of Exendin-4.
- Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study.
- Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway.
- Centrally administered GLP-1 analogue improves intestinal barrier function through the brain orexin and the vagal pathway in rats.
- Distinct effects of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist on islet morphology and function.
- The effect of subcutaneous dulaglutide on weight loss in patients with Type 2 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials.
- The effects of Exendin-4 on bone marrow-derived mesenchymal cells.
- Automated recognition and quantification of pancreatic islets in Zucker diabetic fatty rats treated with exendin-4.
- Weight loss associated with semaglutide treatment among people with HIV.
- The fetal origins of the metabolic syndrome: can we intervene?
- Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review.
- Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial.
- The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.
- Role of glucagon-like peptide- 1 in vascular endothelial dysfunction.
- Effects of exenatide therapy on insulin resistance in the skeletal muscles of high-fat diet and low-dose streptozotocin-induced diabetic rats.
- Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.
- Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure.
- Tirzepatide reduces body weight by increasing fat utilization via the central nervous system-adipose tissue axis in male mice.
- The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials.
- Changes in Basal and Bolus Insulin Requirements with Tirzepatide as an Adjunctive Therapy in Adults with Type 1 Diabetes Using Tandem Control-IQ.
- Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
- Microneedle patch with pure drug tips for delivery of liraglutide: pharmacokinetics in rats and minipigs.
- Liraglutide (Saxenda) for Weight Loss.
- Weight loss and body composition after compounded semaglutide treatment in a real world setting.
- GLP-1R agonists: recent advances, current gaps, and future challenges.
- The effects of a GLP-1 analog liraglutide on reward value and the learned inhibition of appetitive behavior in male and female rats.
- Drug Delivery Strategies for Enhancing the Therapeutic Efficacy of Toxin-Derived Anti-Diabetic Peptides.
- A GIP/xenin hybrid in combination with exendin-4 improves metabolic status in db/db diabetic mice and promotes enduring antidiabetic benefits in high fat fed mice.
- The promise of tirzepatide: A narrative review of metabolic benefits.
- Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice Experiment.
- Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist.
- Tirzepatide attenuates mammary tumor progression in diet-induced obese mice.
- Plasma proteomics reveals an improved cardio-metabolic profile in patients with type 2 diabetes post-liraglutide treatment.
- Tirzepatide for overweight and obesity management.
- ONE MONTH WEIGHT LOSS PREDICTS THE EFFICACY OF LIRAGLUTIDE IN OBESE PATIENTS: DATA FROM A SINGLE CENTER.
- Predictors and correlates of systolic blood pressure reduction with liraglutide treatment in patients with type 2 diabetes.
- Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data.
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND).
- Liraglutide abrogates nephrotoxic effects of chemotherapies.
- The Effect of Liraglutide on β-Blockade for Preventing Variceal Bleeding: A Case Series.
- Tirzepatide and health-related quality of life in adults with obesity or overweight: Results from the SURMOUNT-3 phase 3 randomized trial.
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.
- Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: A prespecified secondary analysis of a randomised clinical trial.
- Up and down waves of glycemic control and lower-extremity amputation in diabetes.